Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi??s Sarcoma

Bodsworth, Neil J.; Bloch, Mark; Bower, Mark; Donnell, David; Yocum, Richard C.

doi:10.2165/00128071-200102020-00004

Cited by 95 publications

(58 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the systemic medications that are American FDA-approved are liposomal daunorubicin, liposomal doxorubicin, paclitaxel and interferon-alpha [97]. Alitretinoin 0.1% gel is approved for topical use [100].…”

Section: Therapymentioning

confidence: 99%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

123

112

View full text Add to dashboard Cite

While there have been many important advances in the study of Kaposi's sarcoma (KS), it remains both a challenge and an enigma in many ways. Kaposi's original description of "multiple idiopathic hemorrhagic sarcoma[s]" in patients who died within 2-3 years resembles KS in AIDS more than classic KS in elderly men of Italian, Jewish, or Mediterranean lineage, in whom the disease is usually benign. KS had been evident in about one-third of those with early AIDS, often as its presenting sign, a pattern markedly reduced in recent times since the introduction of highly active anti-retroviral therapy (HAART). The most important advance has been the convincing etiologic linkage of KS with human herpesvirus 8 (HHV-8), which is necessary but not sufficient. It has a low prevalence in the general population of the USA and UK, with an intermediate rate in Italy and Greece, and a high one in Uganda. KS risk may be significantly lower in AIDS patients with a history of anti-herpes therapy. Many aspects of HHV-8, including its transmission pattern and different genospecies, are being scrutinized. The diagnosis of KS may be difficult. One should be aware of KS clinical variants, including telangiectatic, eccymotic, and keloidal KS. One must consider a number of other disorders, including bacillary angiomatosis. HHV-8 DNA sequences in dermatofibromas and other tumors should probably not be viewed as representing a marker for KS. Therapeutic options vary for KS. Intralesional and low-dose outpatient intravenous vinblastine may be valuable, as immunosuppression with KS is not a good idea if it can be avoided. Anti-herpes virus therapy may have potential for wide use, especially in preventing the development of KS in at risk populations, such as HHV-8 seropositive individuals undergoing transplantation surgery.

show abstract

Section: Therapymentioning

confidence: 99%

Kaposi's sarcoma: An update

Schwartz

2004

Journal of Surgical Oncology

123

112

View full text Add to dashboard Cite

show abstract

“…In addition to its approved use, alitretinoin has been reported to be beneficial also in refractory pityriasis rubra pilaris [6] , lichen planus [7,8] , cutaneous lupus erythematosus [9] , palmoplantar pustular psoriasis [10] as well as in mycosis fungoides [11] , but it appeared to have a mixed effect in congenital ichthyosis [12] . Several studies have also been carried out with alitretinoin used in the treatment of AIDS-related Kaposi's sarcoma [13] .…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Gadaldi

Erdemoglu²,

Yawalkar³

2015

Dermatology

View full text Add to dashboard Cite

Background: Chronic itch with secondary scratch lesions such as prurigo has a major impact on quality of life. Due to its relapsing nature and often unknown origin, its treatment is challenging. Objective: We sought to demonstrate that alitretinoin can be an efficacious and well-tolerated treatment in a patient suffering from chronic itch with concomitant prurigo and psoriatic lesions. Methods: Case report. Results: After 1 month of alitretinoin treatment (30 mg daily), itch as well as prurigo and psoriasis lesions decreased markedly. Three cycles of alitretinoin were administered, as each cessation of treatment led to relapse of the symptoms after 6-8 weeks. Tapering of the alitretinoin dose (30 mg every second day) after the third cycle allowed to maintain the effects for over 18 months. Conclusion: Treatment of refractory prurigo with alitretinoin might be an efficacious alternative to standard therapies. In case of relapse, retreatment with alitretinoin reinduces a further long-lasting response.

show abstract

“…It has been approved since 1999 for the treatment of Kaposi sarcoma, but has not been evaluated in any complete study for the treatment of MF. [82][83][84] In the 1990s, 2 phase I/II trials were performed to evaluate the effect of topical bexarotene and topical alitretinoin in MF. The study found that 7 patients had some response to topical alitretinoin 0.1% gel with twice-daily applications.…”

Section: Alitretinoinmentioning

confidence: 99%

“…84 Adverse cutaneous reactions of all the topical retinoids are similar, with the most frequent symptoms being local dryness, burning, erythema, and desquamation. 75,76,[82][83][84] Vesiculobullous eruptions have also occurred with topical bexarotene use. 85 Rarely, allergic contact dermatitis occurs with topical retinoids.…”

Section: Alitretinoinmentioning

confidence: 99%

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Nguyen

Bohjanen

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Early stage mycosis fungoides represents the most common clinical presentation of cutaneous lymphoma, with skin-directed therapies long established in its treatment. These therapies continue to change as new treatment regimens emerge. Other skin-directed treatments include light and radiation therapy. Therapies with higher levels of evidence and less systemic toxicity are usually preferred as first-line treatment. However, even these established therapies, like topical corticosteroids and carmustine, lack randomized clinical trials to establish their efficacy. Research is also needed to further define the role of combination topical therapies and how skin-directed therapies can be used as adjuvants to systemic medications.

show abstract

Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi??s Sarcoma

Abstract: The results of this study provide convincing evidence of the superiority of alitretinoin gel over vehicle gel for the treatment of the cutaneous lesions of AIDS-related KS.

Cited by 95 publications

References 22 publications

Kaposi's sarcoma: An update

Kaposi's sarcoma: An update

Successful Treatment of Recalcitrant Prurigo with Alitretinoin

Skin-Directed Therapies in Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About